Measuring value. Improving decisions. Creating impact.

As genomic sequencing transitions into mainstream healthcare, critically appraising its value is key to informing evidence-based policy, practice and implementation strategies. Assessing the value of genomics is challenging, as traditional evaluation methods and frameworks do not capture many of the outcomes of genomics. This includes the personal value that genomic information provides individuals and family members, and the potential to reuse sequencing data to improve clinical care and drive research. Evaluation is hampered by lack of standardised outcome measures, small sample sizes, and uncertainties arising from the evolving nature of the technology, its applications and associated costs. Complex health system factors further influence real-world utilisation and the value of genomic technologies and services within resource-constrained settings.

A conversation on the complexities of health, economics and ethics in genomics: what genomic testing is worth, who decides, and how those judgements reach the clinic. Recorded for the Royal College of Pathologists of Australasia.

On the DIRECT checklist, a reporting standard for discrete choice experiments in health published in PharmacoEconomics in 2024, and now a submission requirement at five leading journals in the field.